Zydus Lifesciences Ltd
₹1188.10
-52.50 (4.23%)
Sat, 07 Nov 2026, 11:24 pm
Health Technology
Pharmaceuticals: Major
24.5KZydus Lifesciences Ratios
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 27.83 | 18.02 | 12.42 | 12.26 | 22.30 | 22.78 | 23.85 | 23.23 | 26.15 | 31.01 | 16.78 | 30.51 | 21.82 | 19.19 | 23.24 | 21.15 | 19.76 | 25.47 | 26.36 | 19.69 |
| Price to book ratio | 6.07 | 4.87 | 3.01 | 3.01 | 6.92 | 7.46 | 6.05 | 5.16 | 6.11 | 8.40 | 5.69 | 6.52 | 4.43 | 3.42 | 2.64 | 3.47 | 2.10 | 2.84 | 5.10 | 3.72 |
| Price to sales ratio | 2.94 | 2.36 | 1.41 | 1.30 | 3.15 | 3.63 | 3.06 | 2.47 | 2.98 | 4.19 | 3.51 | 4.89 | 3.30 | 2.74 | 1.95 | 3.16 | 2.37 | 2.93 | 5.28 | 3.90 |
| Price to cash flow ratio | 38.15 | 16.71 | 17.24 | 16.96 | 17.80 | 25.84 | 41.65 | 33.08 | 27.25 | 36.78 | 16.97 | 34.54 | 44.84 | 12.42 | 10.32 | 14.29 | 17.40 | 18.91 | 30.98 | 12.97 |
| Enterprise value | 4643Cr | 4587Cr | 3969Cr | 4772Cr | 12143Cr | 17048Cr | 17463Cr | 17531Cr | 23253Cr | 37641Cr | 34188Cr | 49148Cr | 42630Cr | 43796Cr | 35446Cr | 50589Cr | 38513Cr | 52094Cr | 103000Cr | 86933Cr |
| Enterprise value to EBITDA ratio | 19.09 | 14.97 | 10.03 | 8.61 | 16.22 | 19.29 | 18.76 | 18.75 | 26.63 | 23.30 | 14.89 | 26.79 | 15.51 | 15.64 | 13.52 | 15.34 | 12.27 | 15.26 | 20.38 | 13.34 |
| Debt to equity ratio | 0.64 | 0.53 | 0.79 | 1.04 | 0.67 | 0.49 | 0.89 | 0.99 | 0.79 | 0.63 | 0.43 | 0.75 | 0.62 | 0.76 | 0.77 | 0.35 | 0.25 | 0.07 | 0.04 | 0.13 |
| Return on equity % | 23.59 | 29.89 | 26.73 | 26.39 | 35.28 | 37.42 | 27.51 | 23.69 | 25.18 | 29.92 | 38.92 | 23.55 | 22.85 | 19.33 | 11.33 | 18.84 | 14.95 | 11.39 | 20.55 | 20.67 |
Zydus Lifesciences Ltd Ratios
The Zydus Lifesciences Ltd Ratios page provides a complete fundamental analysis of Zydus Lifesciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Zydus Lifesciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE, BSE: 532321) is currently trading at ₹1188.10, with a market capitalization of ₹123590.72Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Zydus Lifesciences Ltd remains a key stock for fundamental analysis using Zydus Lifesciences Ltd Ratios.
Zydus Lifesciences Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Zydus Lifesciences Ltd P/E ratio currently stands at 19.69, making it one of the most tracked metrics in Zydus Lifesciences Ltd Ratios.
Historically, the Zydus Lifesciences Ltd P/E ratio has shown strong fluctuations:
- 2025: 19.69
- 2024: 26.36
- 2023: 25.47
- 2022: 19.76
- 2021: 21.15
The decline in Zydus Lifesciences Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Zydus Lifesciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.72.
Historical P/B trend:
- 2025: 3.72
- 2024: 5.10
- 2023: 2.84
- 2022: 2.10
Zydus Lifesciences Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Zydus Lifesciences Ltd P/S ratio currently stands at 3.90, an important part of Zydus Lifesciences Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 3.90
- 2024: 5.28
- 2023: 2.93
- 2022: 2.37
A stable or declining Zydus Lifesciences Ltd P/S ratio indicates cautious market sentiment.
Zydus Lifesciences Ltd Price to Cash Flow Ratio (P/CF)
The Zydus Lifesciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 12.97.
Historical Zydus Lifesciences Ltd Price to Cash Flow Ratio:
- 2025: 12.97
- 2024: 30.98
- 2023: 18.91
- 2022: 17.40
- 2021: 14.29
The declining Zydus Lifesciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Zydus Lifesciences Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Zydus Lifesciences Ltd EV currently stands at ₹86933Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 86933Cr
- 2024: 103000Cr
- 2023: 52094Cr
- 2022: 38513Cr
Zydus Lifesciences Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Zydus Lifesciences Ltd EV/EBITDA ratio is currently 13.34, a key metric in Zydus Lifesciences Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 13.34
- 2024: 20.38
- 2023: 15.26
- 2022: 12.27
Stable Zydus Lifesciences Ltd EV/EBITDA indicates balanced valuation.
Zydus Lifesciences Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Zydus Lifesciences Ltd D/E ratio is currently 0.13, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0.13
- 2024: 0.04
- 2023: 0.07
- 2022: 0.25
Zydus Lifesciences Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Zydus Lifesciences Ltd ROE currently stands at 20.67%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 20.67
- 2024: 20.55
- 2023: 11.39
- 2022: 14.95
Zydus Lifesciences Ltd demonstrates strong profitability and efficient capital utilization.
Zydus Lifesciences Ltd Ratios Analysis Summary
The Zydus Lifesciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Zydus Lifesciences Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Zydus Lifesciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
